Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. SLFN11, far from being limited to responding to cancer DNA damage.Clinical and experimental medicine · 2025
   Review
2. MET and SLFN11 as a Players in the SCLC Molecular Subtyping Game.International journal of molecular sciences · 2025
   Article
3. SLFN12 Expression Significantly Effects the Response to Chemotherapy Drugs in Triple-Negative Breast Cancer.Cancers · 2024
   Article
4. [Advances in Molecular Subtyping, Characteristics and Therapeutic Strategies of 
Small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023
   Review
5. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance.Cancers · 2022
   Review
6. Schlafens: Emerging Proteins in Cancer Cell Biology.Cells · 2021
   Review
7. Molecular profiles of small cell lung cancer subtypes: therapeutic implications.Molecular therapy oncolytics · 2021
   Review
8. Schlafen 12 Is Prognostically Favorable and Reduces C-Myc and Proliferation in Lung Adenocarcinoma but Not in Lung Squamous Cell Carcinoma.Cancers · 2020
   Article
9. Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research.Journal of clinical medicine · 2020
   Review
10. Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints.Seminars in immunology · 2019
    Review

Corrections and comments

• Comment on
  Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.2018

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.